Whereas SIRT1 inhibition did not sensitize hepatocarcinoma cell lines to sorafenib, SIRT1 overexpression led to decreased apoptosis after sorafenib treatment via increasing deacetylation of p53 and could, therefore, be a potential mechanism for HCC cells to acquire sorafenib resistance. Here, SIRT1 is linked to hepatocellular carcinoma.